Intra-articular etanercept treatment in inflammatory arthritis: A randomized double-blind placebo-controlled proof of mechanism clinical trial validating TNF as a potential therapeutic target for local treatment - 07/10/15
, Danielle Gerlag a, Koen Vos a, c, Margriet Vervoordeldonk b, Robert Landewé a, d, Paul Peter Tak b, e, f, gBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
There is an increased interest in developing gene therapy approaches for local delivery of therapeutic genes in patients with arthritis. Intra-articular (i.a.) gene delivery, using an adeno-associated virus encoding a TNF soluble receptor, resulted in reduced paw swelling in an arthritis animal model, but i.a. treatment with a similar vector did not induce robust clinical improvement in patients. It is unclear whether this can be explained by for instance insufficient transduction efficiency or the fact that TNF is not a good therapeutic target for i.a treatment. The objective of this study was to explore the effects of i.a TNF blockade.
Methods |
Thirty-one patients with rheumatoid or psoriatic arthritis were assigned to a single i.a. injection of 25mg etanercept or placebo in a double-blind randomised controlled clinical trial. The primary end point was target joint improvement, determined by a composite change index.
Results |
Twenty-two patients received etanercept and 9 received placebo. Treatment was generally well tolerated. Treatment with etanercept resulted in a prompt and statistically significant improvement of the index (P<0.001) in comparison with placebo. As expected in light of the half-life of etanercept, the beneficial effect was transient and only statistically significant at week 1 and 2 after i.a. injection.
Conclusion |
The results support the development of novel approaches for long-term inhibition of TNF at the site of inflammation, such as gene therapy.
Trial registration |
The Netherlands National Trial Register (NTR), www.trialregister.nl/, NTR-1210.
Le texte complet de cet article est disponible en PDF.Keywords : Intra-articular therapy, Rheumatoid arthritis, Psoriatic arthritis, Etanercept, TNF blockade, Gene therapy
Abbreviations : AMC-UvA, ACR, AS, Anti-CCP, CASPAR, CCI, CRP, DMARD, ESR, HAQ-DI, MUMC, MCP, NTR, PsA, RCT, RA, TJC, UMCG, VAS
Plan
Vol 82 - N° 5
P. 338-344 - octobre 2015 Retour au numéro
Article précédent
- Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers
- Thierry Lequerré, Émilie Farran, Jean-François Ménard, Macha Kozyreff-Meurice, Thibault Vandhuick, Christine Tharasse, Sophie Pouplin, Alain Daragon, Xavier Le Loët, Rémi Varin, Olivier Vittecoq
- Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort
- Maxime Dougados, Adrien Etcheto, Anna Molto, Sandrine Alonso, Sophie Bouvet, Jean-Pierre Daurès, Paul Landais, Maria-Antonietta d’Agostino, Francis Berenbaum, Maxime Breban, Pascal Claudepierre, Bernard Combe, Bruno Fautrel, Antoine Feydy, Philippe Goupille, Pascal Richette, Thao Pham, Christian Roux, Jean-Marc Treluyer, Alain Saraux, Désirée van der Heijde, Daniel Wendling
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?